Sign up USA
Proactive Investors - Run By Investors For Investors

Unilife soars on licensing deal with Amgen

Other interested parties have been told they are out of luck after Unilife decided on Amgen as its partner
Unilife soars on licensing deal with Amgen
Shares in Unilife were the top performers on Nasdaq

Shares in medtech firm Unilife (NASDAQ:UNIS) soared after it penciled in a licensing deal with Amgen (NASDAQ:AMGN).

The company had previously announced a review of potential strategic alternatives, but appears now to have made its mind up to get into bed with Amgen, having entered into an exclusivity agreement with the biotech giant.

Amgen has stumped up a non-refundable US$15mln deposit in return for a perpetual, worldwide non-exclusive license to use Unilife wearable injector devices for use with certain large volume drug products of Amgen.

In addition, Amgen has been granted a perpetual, worldwide exclusive license to develop, manufacture and supply Unilife's one millilitre (1ml) wearable injector for use with certain small volume drug products, most of which will be developed and manufactured by Unilife.

Unilife will receive an amount for each device it manufactures for Amgen, based on annual volumes and device features, though Amgen will be able to outsource up to 20% of the production, albeit while paying a royalty to Unilife on each device.

Shares in Unilife were the top performers on Nasdaq, jumping 58% to 78.01 cents.

View full UNI profile View Profile

Unilife Medical Solutions Limited Timeline

Newswire
February 22 2016

Related Articles

Workers at CERN
September 29 2017
The technology being developed is cheaper and smaller than the current units, which are almost prohibitively expensive
1507647205_biotech_517925923.jpg
October 10 2017
Last month the group revealed its Barocycler 2320EXTREME device had been selected as a finalist in the prestigious R&D 100 Awards for 2017.
diagram of the human microbiome
September 13 2017
OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2017. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use